PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials. Biomed. Res. Ther. 2023;10(12):6090-6102. doi:10.15419/bmrat.v10i12.851